Notable Quotes
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >
"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >
"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >
"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >
"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More >
MLV & Co. Disclosures:
Agenus Inc.:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for Agenus Inc. MLV or any affiliates in the past 12 months received compensation for investment banking services from Agenus Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Agenus Inc. in the next three months.
Peregrine Pharmaceuticals Inc:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for Peregrine Pharmaceuticals Inc. MLV or any affiliates in the past 12 months received compensation for investment banking services from Peregrine Pharmaceuticals Inc. MLV or any affiliates in the past 12 months received compensation for products or services other than investment banking services from
Peregrine Pharmaceuticals Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Peregrine Pharmaceuticals Inc. in the next three months.
ArQule Inc.:
MLV or any affiliates in the past 12 months received compensation for products or services other than investment banking services from ArQule Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from ArQule Inc. in the next three months.
Acadia Pharmaceuticals Inc.:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for Acadia Pharmaceuticals Inc. MLV or any affiliates in the past 12 months received compensation for investment banking services from Acadia Pharmaceuticals Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Acadia Pharmaceuticals Inc. in
the next three months.
Keryx Pharmaceuticals Inc.:
MLV or any affiliates in the past 12 months received compensation for products or services other than investment banking services from Keryx Biopharmaceuticals Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Keryx Biopharmaceuticals Inc. in the next three months.
Threshold Pharmaceuticals:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for Threshold Pharmaceuticals Inc. MLV or any affiliates in the past 12 months received compensation for investment banking services from Threshold Pharmaceuticals Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Threshold Pharmaceuticals Inc. in the next three months.
Dynavax technologies Corp.:
MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Dynavax Technologies Corp. in the next three months.
Genomic Health Inc.:
MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Genomic Health Inc. in the next three months.
Resverlogix Corp.:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for Resverlogix Corp. MLV or any affiliates in the past 12 months received compensation for investment banking services from Resverlogix Corp. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Resverlogix Corp. in the next three months.
Aastrom Biosciences Inc.:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for Aastrom Biosciences Inc. MLV or any affiliates in the past 12 months received compensation for investment banking services from Aastrom Biosciences Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Aastrom Biosciences Inc. in the next three months.
Prana Biotechnology Ltd.:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for Prana Biotechnology Ltd. MLV or any affiliates in the past 12 months received compensation for investment banking services from Prana Biotechnology Ltd. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Prana Biotechnology Ltd. in the next three months.
BioCryst Pharmaceuticals Inc.:
MLV or any affiliates in the past 12 months managed or co-managed a public offering of securities for BioCryst Pharmaceuticals Inc. MLV or any affiliates in the past 12 months received compensation for investment banking services from BioCryst Pharmaceuticals Inc. MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from BioCryst Pharmaceuticals Inc. in the next three months.
Spectrum Pharmaceuticals Inc.
MLV or any affiliates expect to receive or intend to seek compensation for investment banking services from Spectrum Pharmaceuticals Inc. in the next three months. MLV or any affiliates in the past 12 months received compensation for products or services other than investment banking services from Spectrum Pharmaceuticals Inc.
More Experts
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >
The Life Sciences Report